The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus
Publication year
2011Source
Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 2, (2011), pp. 458-463ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Pharmacology-Toxicology
Intensive Care
Clinical Pharmacy
Dentistry
Internal Medicine
Journal title
Arteriosclerosis, Thrombosis, and Vascular Biology
Volume
vol. 31
Issue
iss. 2
Page start
p. 458
Page end
p. 463
Subject
IGMD 5: Health aging / healthy living N4i 1: Pathogenesis and modulation of inflammation; N4i 1: Pathogenesis and modulation of inflammation IGMD 9: Renal disorder; N4i 2: Invasive mycoses and compromised host; N4i 3: Poverty-related infectious diseases NCEBP 13: Infectious diseases and international health; NCEBP 14: Cardiovascular diseases; NCMLS 3: Tissue engineering and pathology; NCMLS 5: Membrane transport and intracellular motility N4i 1: Pathogenesis and modulation of inflammationAbstract
OBJECTIVE: In type 2 diabetes mellitus (T2DM), oxidative stress gives rise to endothelial dysfunction. Bilirubin, a powerful endogenous antioxidant, significantly attenuates endothelial dysfunction in preclinical experiments. The Gilbert syndrome is accompanied by a mild and lifelong hyperbilirubinemia and associated with only one third of the usual cardiovascular mortality risk. The hyperbilirubinemia caused by atazanavir treatment closely resembles the Gilbert syndrome. We thus hypothesized that treatment with atazanavir would ameliorate oxidative stress and vascular inflammation and improve endothelial function in T2DM. METHODS AND RESULTS: In a double-blind, placebo-controlled crossover design, we induced a moderate hyperbilirubinemia by a 3-day atazanavir treatment in 16 subjects experiencing T2DM. On the fourth day, endothelial function was assessed by venous occlusion plethysmography. Endothelium-dependent and endothelium-independent vasodilation were assessed by intraarterial infusion of acetylcholine and nitroglycerin, respectively. Atazanavir treatment induced an increase in average bilirubin levels from 7 mumol/L (0.4 mg/dL) to 64 mumol/L (3.8 mg/dL). A significant improvement in plasma antioxidant capacity (P<0.001) and endothelium-dependent vasodilation (P=0.036) and a decrease in plasma von Willebrand factor (P=0.052) were observed. CONCLUSIONS: Experimental hyperbilirubinemia is associated with a significant improvement of endothelial function in T2DM.
This item appears in the following Collection(s)
- Academic publications [203793]
- Electronic publications [102109]
- Faculty of Medical Sciences [80320]
- Open Access publications [70806]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.